We also retrospectively assessed the correlations between AXL expression and the clinical efficacy of the first- and second-generation EGFR-TKIs and osimertinib in 46 patients with EGFR-mutated NSCLC and in 11 patients with EGFR-mutated NSCLC harboring the T790M mutations, respectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.